In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic macular edema at 1 year.
Donald J. D'Amico, MD
Advertisement
Donald J. D'Amico, MD, Professor and chairman, Weill Cornell Medical Campus; ophthalmologist and chief, New York Presbyterian Hospital.
Articles by Donald J. D'Amico, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
Keynote Address Tackles AI’s Role in Health Care, Eye Care
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5